Skip to content

NASDAQ · micro · thesis board

IMAB I-Mab

Bispecific immuno-oncology

View race

Thesis

Editorial summary — not a primary filing

Bispecific / immuno-oncology assets with partner leverage; financing risk elevated.

Next gate

2027-04-12EstimatedPh2 readout

Dose escalation

242 days · Estimated: Estimated window

Survive-to-Event

ok

Cash covers the next gate with ~3 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~342d)100%
Days to gate (242d)71%
Show math

$180M cash ÷ $16M/mo burn ≈ 342 days. Source: curated SEC quarter figures.

Cash $180M as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved

Rivals in this race

Open race →
AZNApprovedokMRKPh3okDAWNPh2ok

Risks

  • Cash
  • Partner terms
  • Clinical binary
  • Listing/liquidity

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT04900818as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01